Home/ Stocks/ IKT

Inhibikase Therapeutics, Inc. Common Stock

IKT XNAS

$1.60 -0.14 (-8.05%) ▼ 15-min delayed

Open

$1.72

High

$1.73

Low

$1.57

Volume

6.31M

Market Cap

$211.00M

About Inhibikase Therapeutics, Inc. Common Stock

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 16 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-11,930,280	$-0.13
Q2 2025	$0	$-9,915,523	$-0.11
Q1 2025	$0	$-13,678,735	$-0.15
FY 2024	$0	$-27,519,886	$-1.16

Earnings & Analyst Ratings

Next Earnings: Tue, May 12, 2026

Calendar →

Related Market News

No specific coverage for IKT yet. Check out our latest market news or earnings calendar.

Get IKT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Inhibikase Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.